Efficacy and tolerability of ustekinumab in patients with ulcerative colitis after failure of first- line therapy with genetically engineered biological agents
Abstract. Article describes a clinical observation of a 49-year-old female patient with 25-year history of severe steroid-dependent ulcerative colitis (UC). The patient had ineffective/intolerant treatment with 5-aminosalicylic acid, glucocorticosteroids, thiopurines, and budesonide MMX. Remission was achieved with etrolizumab (4.5 years), but a relapse occurred after its discontinuation. During an exacerbation of UC (April 2023, Mayo 3), ustekinumab was prescribed: induction – 6 mg per kilogram intravenously, maintenance therapy – 90 mg subcutaneously every 12 weeks. As a result, it was possible to achieve stable clinical remission lasting 2 years. Endoscopy (April 2025) showed minimal UC activity (Mayo 1), histological examination – disease activity of 2 points according to Riley with the signs of healing. Thus, ustekinumab effectively induced and maintained remission in a female patient with UC refractory to the therapy by genetically engineered biological medicinal product of the first line.Iakovlev A.A., Volkov A.S., Bashtovaya O.A.
Keywords
ulcerative colitis
genetically engineered biological medicinal products
first-line therapy for ulcerative colitis
ustekinumab
References
1. Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А., Решетов И.В., Маев И.В., Ачкасов С.И. с соавт. Язвенный колит (К.51), взрослые. Колопроктология. 2023;22(1):10–44. (Shelygin YuA, Ivashkin VT, Belousova EA, Reshetov IV, Maev IV, Achkasov SI et al. Ulcerative colitis (K.51), adults. Koloproktologiya = Coloproctology. 2023;22(1):10–44 (In Russ.)).
EDN: GDYCMT. https://doi.org/0.33878/2073-7556-2023-22-1-10-44
2. Князев О.В., Шкурко Т.В., Фадеева Н.А., Бакулин И.Г., Бордин Д.С. Эпидемиология хронических воспалительных заболеваний кишечника. Вчера, сегодня, завтра. Экспериментальная и клиническая гастроэнтерология. 2017;(3):4–12. (Knyazev OV, Shkurko TV, Fadeeva NA, Bakulin IG, Bordin DS. Epidemiology of chronic inflammatory disease. Yesterday, today, tomorrow. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2017;(3):4–12 (In Russ.)). EDN: ZRPJFX.
3. Водовозов А. Современный подход к терапии язвенного колита: обновленные рекомендации Американской гастроэнтерологической ассоциации. Ремедиум. 2021;(2):62–68. (Vodovozov A. Modern approach to the treatment of ulcerative colitis: Updated recommendations of the American Gastroenterological Association. Remedium. 2021;(2):62–68 (In Russ.)).
EDN: SLRGAN. https://doi.org/10.21518/1561-5936-2021-2-62-68
4. Kochhar GS, Desai A, Farraye FA, Cross RK, El-Hachem S, Dulai PS, Regueiro M. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study. Aliment Pharmacol Ther. 2023;58(3):297–308.
PMID: 37300328. https://doi.org/10.1111/apt.17570
5. Bhattacharya A, Osterman MT. Biologic therapy for ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):717–29.
PMID: 33121691. https://doi.org/10.1016/j.gtc.2020.08.002
6. Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–70.
PMID: 34856198. https://doi.org/10.1016/S2468-1253(21)00377-0
7. Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A et al. Effectiveness of ustekinumab for patients with moderate-to-severe ulcerative colitis: A multicenter real-world Canadian Study. Am J Gastroenterol. 2024.
PMID: 39657015. https://doi.org/10.14309/ajg.0000000000003212
8. Burbage S, Knight H, Godwin B, Meadows R, Jones W, Zhao R, Kachroo S. The real-world effectiveness of ustekinumab in patients with ulcerative colitis in the United States. Curr Med Res Opin. 2025;41(4):683–89.
PMID: 40327500. https://doi.org/10.1080/03007995.2025.2494642
9. Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR et al.; HIBISCUS Study Group. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): Two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022;7(1):17–27.
PMID: 34798036. https://doi.org/10.1016/S2468-1253(21)00338-1
10. Motawea KR, Abdelghafar YA, AbdelQadir YH, Aboelenein MM, Ibrahim N, Belal MM et al. Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta-analysis. Health Sci Rep. 2024;7(5):e882.
PMID: 38736478. PMCID: PMC11082092. https://doi.org/10.1002/hsr2.882
11. Taxonera C, Olivares D, López-García O.N, Alba C. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–19.
PMID: 36645145. https://doi.org/10.1111/apt.17386
About the Authors
Alexey A. Iakovlev, MD, Dr. Sci. (Medicine), professor, head of the Department of gastroenterology and endoscopy, Rostov State Medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane.E-mail: gastroklinika@yandex.ru
ORCID: https://orcid.org/0000-0003-1697-8989. Scopus ID: 56848047500. eLibrary SPIN: 4699-2807
Alexander S. Volkov, MD, PhD (Medicine), associate professor of the Department of gastroenterology and endoscopy, Rostov State Medical University of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane.
E-mail: medicina_volkov@mail.ru
ORCID: https://orcid.org/0009-0000-3227-1225. Scopus ID: 56343187600. eLibrary SPIN: 1718-1989
Olga A. Bashtovaya, MD, gastroenterologist at the Department of therapy No. 1, Clinic of Rostov state medical university of the Ministry of Healthcare of Russia. Address: 344022, Rostov-on-Don, 29 Nakhichevansky Lane.
E-mail: gastro_olga@mail.ru
ORCID: https://orcid.org/0000-0003-1629-2936. eLibrary SPIN: 3829-7735
Similar Articles
